ArticleAmerican journal of translational research2021
Study on the effects of desloratadine citrate disodium on the postoperative complications and inflammatory response in patients with chronic sinusitis undergoing endoscopic sinus surgery.
Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 5 citations in OpenAlex.
- Efficacy, safety, and serum cytokine modulation by olopatadine hydrochloride and desloratadine citrate disodium combination therapy in urticaria.American journal of translational research · 2024Article
- Effects of Endoscopic Sinus Surgery Combined with Budesonide Treatment on Nasal Cavity Function and Serum Inflammatory Factors in Patients with Chronic Sinusitis.Journal of healthcare engineering · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the effects of desloratadine citrate disodium on the postoperative complications and inflammatory markers in patients with chronic sinusitis undergoing endoscopic sinus surgery.
methodsFrom June 2019 to December 2020, the patients with chronic sinusitis who received treatment in our hospital were selected and divided into the control group (CG) and experimental group (EG). In both groups, patients were given endoscopic sinus surgery. On this basis, patients were treated with desloratadine citrate disodium in the EG. The total effective rate of the operation and the incidence of complications were compared between the two groups, and the VAS scores of clinical symptoms were compared between the two groups after treatment. Meanwhile, the changes of serum TIgE, ECP and inflammatory factors were compared between the two groups, and the nasal mucociliary clearing function was compared between the two groups before and after treatment.
resultsAfter treatment, the total effective rate was 94.9% in the EG, which was significantly higher than that in the CG (82.2%). The levels of serum interleukin-6 (IL-6), interleukin-8 (IL-8), high-sensitivity C-reactive protein (hs-CRP) and tumor necrosis factor-α (TNF-α) in the EG were significantly lower than those in the CG, and the levels of serum TIgE and ECP were also significantly lower than those in the CG. After treatment for 3 months, the mucociliary clearance rate and mucociliary clearance rate in the EG were significantly higher than those in the CG, while the saccharin clearance time was significantly shorter than that in the CG. The incidence of complications in the EG was significantly lower than that in the CG (all P < 0.05).
conclusionDesloratadine citrate disodium combined with endoscopic sinus surgery can improve the clinical efficacy, reduce the level of inflammatory factors and effectively reduce the incidence of complications in patients with chronic sinusitis.
Indexed as
Identifiers
33841709PMC8014428W3152736262What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.